AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$TNON

HRT FINANCIAL LP sold $57K of TNON

HRT FINANCIAL LP sold 8,299 shares of Tenon Medical, Inc. (TNON) at an average of $6.91 ($4.66–$7.90) across 3 trades over 2026-08-28 to 2026-08-31.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Sep 1, 2026, 8:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TNON
Neutral
high confidence
Mentioned
$TNON
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TNONNeutralLow
01

Why it matters

The disclosed sale is modest and does not indicate material insider sentiment.

02

Market read

Small insider sale with limited trading relevance.

03

What to watch

Potential upcoming FDA decisions could affect future insider activity.

Relevance 3/10Novelty 4/10Timing: filed Sep 1 2026

Background

Form 4 filings disclose insider transactions; investors monitor large sales for signals.

Company-level read

Ticker impact

$TNONNeutralHigh confidence
Context

HRT Financial LP sold 8,299 shares of Tenon Medical (TNON) for $57,334, a Form 4 insider sale.

Expected impact

No significant price impact expected.

Evidence & confidence

The transaction size is small relative to market cap and typical daily volume.

Market effects

Sector

None; Tenon Medical operates in a niche medical device segment.

Regional

No regional effect.

Global

Minimal.

Counterpoint

What could challenge this read

If insider selling signals concerns, a short position could be considered, but size is too small to justify.

Key entities

  • Company
    Tenon Medical, Inc.

    Medical device manufacturer listed on NASDAQ (TNON).

  • Insider
    HRT Financial LP

    10% owner of Tenon Medical reporting a sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TNON insider trading history →

Related articles

SEP 11
$TNONHigh

Tenon Medical TNON Jumps As Debt Risk Fades

Tenon Medical Inc. (NASDAQ: TNON) shares surged 53.64% after repaying $5.16M in convertible notes, reducing debt risk. The company reported Q2 2026 revenue of $1.3M, up 127% YoY, with a 64% gross margin. Despite strong growth, TNON faces financial challenges, including a $4.05M net loss and negative equity. Traders are monitoring the stock due to its volatility and recent catalysts, such as FDA clearance and increased surgical volume.

timothysykes.com3 min
SEP 11
$TNONHigh

Tenon Medical TNON Jumps After Early Debt Repayment

Tenon Medical Inc. (TNON) shares rose 55.66% after repaying $5.16M in convertible notes early. The company reported Q2 2026 revenue of $1.3M, up 127% YoY, with a 64% gross margin, but a net loss of $4.05M. TNON's stock is highly volatile, driven by news and liquidity rather than fundamentals.

stockstotrade.com2 min
SEP 11
$TNONHigh

Tenon Medical TNON Stock Jumps As Debt Overhang Vanishes

Tenon Medical Inc. (TNON) stock surged 56.04% on September 11, 2026, following the company's repayment of $5.16M in convertible notes, removing a dilution risk. Q2 revenue grew 127% YoY to $1.3M, with a 64% gross margin, but the company remains unprofitable. TNON regained Nasdaq compliance and reported record surgical case volume.

stockstotrade.com3 min
SEP 11
$TNONHigh

Tenon Medical TNON Jumps As Debt Overhang Clears

Tenon Medical Inc. (TNON) shares rose 55.66% after the company cleared $5.16M in debt ahead of schedule, improving its balance sheet. The stock has shown high volatility, with a recent surge from $2.44 to $5.30. TNON reported Q2 2026 revenue growth of 127% YoY to $1.3M, but remains unprofitable with a net loss of $4.1M. The company secured FDA clearance for a medical device and regained Nasdaq compliance, but faces liquidity challenges and potential future capital raises.

timothysykes.com2 min